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Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways DOI: 10.1111/bjd.18001 DEAR EDITOR, Methotrexate (MTX) is one of the most frequently used conventional systemic therapies for the treatment of moderate-to-severe plaque-type psoriasis. Although it has been available since the 1950s, 1 3 with approximately 30% of patients treated with SC MTX achieving a 90% reduction in PASI score after 1 year of therapy. We report further details from a substudy (n = 27/120 patients) of this placebo-controlled phase III clinical trial (EudraCT number 2012-002716-10). Punch biopsies (4 mm) of representative plaques were taken at baseline and after 16 weeks of therapy, and investigated blinded by histology and immunohistochemistry for changes in the epidermal microarchitecture (parakeratosis, epidermal thickness, presence of Munro's microabscesses, Ki-67) and markers of the inflammatory infiltrate (CD1a, CD3, CD11c). Quantitative real-time polymerase chain reaction was used to determine cutaneous levels of dominant cytokine circuits [interleukin (IL)-17A, interferon (IFN)-c, tumour necrosis factor (TNF)-a] before and after treatment. 4, 6 The study was approved by the ethical committees of the participating centres and informed consent was obtained from all patients. Findings were obtained from three patient subgroups based on their treatment and clinical response. Six of 27 patients (23%) received placebo; seven of 27 (26%) received MTX but did not achieve a PASI 75 response (MTX nonresponders); and 14 of 27 (52%) received MTX and were PASI 75 responders (MTX responders). We found significant reductions in markers of psoriatic epidermal pathology and in infiltrating CD3 + T cells and CD11c + dendritic cells in patients responding to MTX but not in MTX nonresponders or patients receiving placebo (Fig. 1a-d) . This was associated with a significant reduction in cutaneous IL-17A (to approximately 12% of baseline values) and IFN-c mRNA levels (to approximately 26% of baseline values) in MTX PASI 75 responders. Inhibitory effects were weaker in MTX nonresponders, and IL-17A and IFN-c mRNA levels were unchanged or increased in placebo patients (Fig. 1e, f) . Numbers of CD1a + cutaneous dendritic cells and skin levels of TNF-a mRNA were similar in the three groups and remained unchanged during treatment. Overall, there was a striking correlation between the individual reduction of cutaneous IL-17A mRNA levels and the clinical response (Fig. 1g) Funding sources: The clinical trial and the biopsy substudy was supported by a grant by Medac, Germany (K.R.). Medac had no influence on the design and conduct of the study, nor the interpretation of the results or the preparation of the manuscript.
